Marksans Pharma Ltd. logo

Marksans Pharma Ltd. (MARKSANS)

Market Closed
12 Dec, 10:00
XNSE XNSE
193. 86
+1.96
+1.02%
102.75B Market Cap
- P/E Ratio
2% Div Yield
585,775 Volume
- Eps
191.9
Previous Close
Day Range
191.3 194.3
Year Range
162 332.4
Want to track MARKSANS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 58 days

Summary

MARKSANS closed yesterday higher at ₹193.86, an increase of 1.02% from Thursday's close, completing a monthly increase of 5.77% or ₹10.58. Over the past 12 months, MARKSANS stock lost -35.12%.
MARKSANS pays dividends to its shareholders, with the most recent payment made on Aug 21, 2025. The next estimated payment will be in In 8 months on Aug 21, 2026 for a total of ₹0.8.
The last earnings report, released on Nov 10, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 09, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

MARKSANS Chart

Similar

Sanofi India Limited
4,242.2
-0.01%
Doms Industries Ltd.
2,571.9
+1.54%
Ramkrishna Forgings Ltd.
516
-0.65%
Rainbow Children's Medicare Pvt. Ltd.
1,386.6
+0.5%
Esab India Ltd.
6,194
-2.63%

Marksans Pharma Ltd. (MARKSANS) FAQ

What is the stock price today?

The current price is ₹193.86.

On which exchange is it traded?

Marksans Pharma Ltd. is listed on XNSE.

What is its stock symbol?

The ticker symbol is MARKSANS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2%.

What is its market cap?

As of today, the market cap is 102.75B.

When is the next earnings date?

The next earnings report will release on Feb 09, 2026.

Has Marksans Pharma Ltd. ever had a stock split?

No, there has never been a stock split.

Marksans Pharma Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Mark B. Saldanha CEO
XNSE Exchange
INE750C01026 ISIN
India Country
852 Employees
1 Aug 2025 Last Dividend
11 Mar 2008 Last Split
- IPO Date

Overview

Marksans Pharma Limited is a prominent global pharmaceutical company with its roots firmly planted in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. Incorporated in 1992, this company has established a significant presence in the pharmaceutical industry, extending its services worldwide with a headquarter in Mumbai, India. With a comprehensive approach towards healing and wellness, Marksans Pharma is dedicated to providing high-quality healthcare solutions across a multitude of therapeutic areas, ensuring a broad spectrum of patients benefit from their products.

Products and Services

  • Analgesics: Marksans Pharma develops and markets pain-relief medications designed to alleviate acute and chronic pain conditions.
  • Benign Prostatic Hyperplasia Treatments: Offering effective solutions for patients suffering from benign prostatic hyperplasia to improve their quality of life.
  • Antidiabetic: Comprehensive antidiabetic range catering to the needs of patients with diabetes, aiming at glucose regulation and management of diabetes-related complications.
  • Epilepsy Medications: Formulations aimed at controlling seizures and improving the well-being of individuals living with epilepsy.
  • Anti-inflammatory: A wide variety of anti-inflammatory drugs to treat inflammation and related conditions, enhancing patient comfort.
  • Hyperparathyroidism Treatments: Solutions targeting the effective management of hyperparathyroidism and its symptoms.
  • Antacids: A range of antacid products designed to relieve discomfort from stomach acid-related conditions.
  • Neurology: Drugs developed for various neurological conditions, supporting brain health and functionality.
  • Cardiovascular: A portfolio of cardiovascular drugs, aimed at treating heart conditions and improving patient heart health.
  • Hormonal Treatments: Products focused on correcting hormonal imbalances and treating diseases related to hormone dysfunction.
  • Oncology: A strong lineup of oncology drugs for the treatment and management of various types of cancer.
  • Gastroenterology: Medications designed to address digestive system disorders, improving gastrointestinal health.
  • Pain Management: Comprehensive solutions for effective pain management, catering to a variety of pain-related conditions.
  • Gynecology: A wide range of products focusing on women's health and gynecological conditions.
  • Antifungal: Treatments aimed at combating fungal infections, promoting skin and nail health.
  • Antiulceratives: Medications developed to treat ulcerative conditions, helping to restore mucosal integrity.
  • Vitamins: A variety of vitamin supplements to support overall health and address vitamin deficiencies.
  • Dermatology: Products designed to treat a variety of skin conditions, ensuring skin health and vitality.
  • Cephalosporins and Injectables: A range of cephalosporin antibiotics and injectable products for treating serious infections.
  • Anti-Allergy and Antibacterial: A robust selection of anti-allergy and antibacterial medications to manage allergies and bacterial infections.
  • Hypertension Treatments: Medications specifically aimed at managing high blood pressure and associated risks.

Contact Information

Address: Grandeur
Phone: 91 22 4001 2000